CMPX
Compass Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.84
−2.91%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -12.8%
- EBIT
- -19.5%
- EPS
- +7.0%
- Free cash flow
- -21.5%
- Operating cash flow
- -21.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- -35.1%
- EPS
- -28.5%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- -36.5%
- EBIT
- -28.6%
- Net income
- -34.7%
- EPS
- -16.7%
- Free cash flow
- -9.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026